Aligos’s MASH Data Look Competitive, But Path Forward Is Unclear

 
• By Joseph Haas
  
Fatty liver disease
Aligos's MASH candidate showed liver fat reduction ability in Phase IIa • Source: Shutterstock

More from Clinical Trials

More from R&D